INOVIO PHARMACEUTICALS, INC. — Form 10-Q
Filed August 12, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 2/100
What the filing says
Jacqueline E. Shea (CEO) and Peter Kies (CFO) certified the Q2 2026 10-Q filing dated August 12, 2026 under Sarbanes-Oxley Rules 13a-15(e), 15d-15(e), and Section 906. Both officers affirmed that the quarterly report contains no untrue material statements, that financial statements fairly present the company's condition, and that disclosure controls and internal financial controls are effective. No material weaknesses, deficiencies, or management fraud were disclosed.
Why this rating
Routine SOX officer certifications are standard quarterly filings, procedurally mandated, and contain no substantive business changes or operational disclosures.
See more from August 12, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.